文献速递中枢神经肿瘤放疗胸部肿瘤放疗姑息放疗与转移瘤

硝酸甘油联合全脑放疗治疗非小细胞肺癌脑转移患者:一项随机、开放标签、2期临床试验

Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-02-12

这项开放标签2期试验将96例非小细胞肺癌脑转移患者按1:1随机分配至硝酸甘油联合全脑放疗组或单纯全脑放疗组,主要终点为治疗后3个月颅内客观缓解率。硝酸甘油组颅内客观缓解率显著高于对照组(56.5% vs 32.7%;RR 1.73;95%CI 1.08-2.78;P=0.024),颅内无进展生存期亦独立延长(27.7 vs 9.6;HR 0.5;95%CI 0.2-0.9;P=0.020),EGFR突变亚组获益显著。

要点

  • 硝酸甘油联合全脑放疗组颅内客观缓解率56.5%,对照组32.7%(RR 1.73;95%CI 1.08-2.78;P=0.024)。
  • 硝酸甘油组颅内无进展生存期27.7 vs 对照组9.6(HR 0.5;95%CI 0.2-0.9;P=0.020)。
  • EGFR突变亚组颅内无进展生存期获益显著(HR 0.4;95%CI 0.2-0.9;P=0.030),总生存无差异。

核心结论

  • 硝酸甘油与放疗同步给药可改善非小细胞肺癌脑转移患者的颅内客观缓解率和颅内无进展生存期。
  • 颅内无进展生存期的获益在EGFR突变患者亚组中显著。

研究设计与样本

  • 开放标签、2期随机临床试验,共纳入96例非小细胞肺癌脑转移患者。
  • 患者按1:1随机分配至硝酸甘油联合全脑放疗组或单纯全脑放疗组,全脑放疗为30 Gy分10次。
  • 硝酸甘油经透皮36 mg贴剂给药,周一至周五使用,贯穿全脑放疗期间(10天)。
  • 主要终点为治疗后3个月评估的颅内客观缓解率。
  • 方案在ClinicalTrials.gov回顾性注册(NCT04338867)。

主要发现

  • 对照组分配50例,硝酸甘油组分配46例;对照组26例(52%)为EGFR突变,硝酸甘油组21例(45.7%)为EGFR突变。
  • 颅内客观缓解率硝酸甘油组56.5%(n=26/46可评估患者)vs 对照组32.7%(n=16/49可评估患者);相对风险1.73;95%CI 1.08-2.78;P=0.024。
  • 颅内无进展生存期硝酸甘油联合全脑放疗组27.7 vs 单纯全脑放疗组9.6;HR 0.5;95%CI 0.2-0.9;P=0.020。
  • 接受全身治疗的患者(n=88)总无进展生存期HR 0.5;95%CI 0.2-0.9;P=0.043。
  • EGFR突变患者亚组颅内无进展生存期HR 0.4;95%CI 0.2-0.9;P=0.030;总生存无差异;硝酸甘油组呕吐发生率显著更高(P=0.016)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hypoxia has been associated with chemoradioresistance secondary to vascular endothelial growth factor receptor induced by hypoxia-induced factor (HIF). Nitroglycerin (NTG) can reduce HIF-1 in tissues, and this may have antiangiogenic, proapoptotic, and antiefflux effects. Particularly, epidermal growth factor-mutated (EGFRm) tumor cell lines have been shown to overexpress both vascular endothelial growth factor and HIF. In this phase 2 study, we evaluated the effect of transdermal NTG plus whole brain radiation therapy (WBRT) in patients with non-small cell lung cancer (NSCLC) with brain metastases (BM). METHODS: This was an open-label, phase 2 clinical trial with 96 patients with NSCLC and BM. Patients were randomized 1:1 to receive NTG plus WBRT (30 Gy in 10 fractions) or WBRT alone. The primary endpoint was intracranial objective response rate (iORR) evaluated 3 months posttreatment. NTG was administered using a transdermal 36-mg patch from Monday through Friday throughout WBRT administration (10 days). The protocol was retrospectively registered at ClinicalTrials.gov (NCT04338867). RESULTS: Fifty patients were allocated to the control group, and 46 were allocated to the experimental group (NTG); among these, 26 (52%) had EGFRm in the control group and 21 (45.7%) had EGFRm in the NTG arm. In terms of the iORR, patients in the NTG group had a significantly higher response compared with controls (56.5% [n = 26/46 evaluable patients] vs 32.7% [n = 16/49 evaluable patients]; relative risk, 1.73; 95% confidence interval [CI], 1.08-2.78; P = .024). Additionally, patients who received NTG + WBRT had an independently prolonged intracranial progression-free survival (ICPFS) compared with those who received WBRT alone (27.7 vs 9.6; hazard ratio [HR], 0.5; 95% CI, 0.2-0.9; P = .020); this positively affected overall progression-free survival among patients who received systemic therapy (n = 88; HR, 0.5; 95% CI, 0.2-0.9; P = .043). The benefit of ICPFS (HR, 0.4; 95% CI, 0.2-0.9; P = .030) was significant in the EGFRm patient subgroup. No differences were observed in overall survival. A significantly higher rate of vomiting presented in the NTG arm of the study (P = .016). CONCLUSIONS: The concurrent administration of NTG and radiation therapy improves iORR and ICPFS among patients with NSCLC with BM. The benefit in ICPFS is significant in the EGFRm patient subgroup.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Arrieta O, Hernández-Pedro N, Maldonado F, et al. Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35157994. doi:10.1016/j.ijrobp.2022.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。